Comprehensive analysis of m6A regulators prognostic value in prostate cancer

N6-methyladenosine (m6A) is the most prevalent RNA modification. While the role of m6A in prostate cancer remains unknown. We aim to measure the effects of m6A methylation regulatory genes during the development and progression of prostate cancer. We collected transcriptome information and gene-leve...

Full description

Saved in:
Bibliographic Details
Published inAging (Albany, NY.) Vol. 12; no. 14; pp. 14863 - 14884
Main Authors Ji, Guangjie, Huang, Cong, He, Shiming, Gong, Yanqing, Song, Gang, Li, Xuesong, Zhou, Liqun
Format Journal Article
LanguageEnglish
Published United States Impact Journals 25.07.2020
Subjects
AlkB Homolog 5, RNA Demethylase - metabolism
Gene Expression Regulation, Neoplastic
Heterogeneous-Nuclear Ribonucleoprotein Group A-B - metabolism
Humans
Male
Methylation
Methyltransferases - genetics
Methyltransferases - metabolism
Prognosis
Progression-Free Survival
Prostatic Neoplasms - genetics
Prostatic Neoplasms - metabolism
Prostatic Neoplasms - pathology
Research Paper
RNA Processing, Post-Transcriptional
RNA-Binding Proteins - metabolism
RNA modification
prostate cancer
N6-methyladenosine
copy number variants
Online AccessGet full text

Cover

Abstract N6-methyladenosine (m6A) is the most prevalent RNA modification. While the role of m6A in prostate cancer remains unknown. We aim to measure the effects of m6A methylation regulatory genes during the development and progression of prostate cancer. We collected transcriptome information and gene-level alteration data from The Cancer Genome Atlas datasets. The log-rank test and Cox regression model were used to examine the prognosis value of m6A methylation regulatory genes of prostate cancer. We discovered that most of m6A methylation regulators were highly expressed in aggressive prostate cancer. Univariable and multivariable Cox regression results showed that the expression of Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3), Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) and N6-adenosine-methyltransferase non-catalytic subunit (METTL14) and copy number variant of AlkB Homolog 5 (ALKBH5) were considerably associated with a recurrence-free survival of prostate cancer. Furthermore, a high level of m6A methylation in mRNA promotes the progression of prostate cancer via regulating subcellular protein localization. Patients with a high level of mRNA methylation resulted from overexpression of reader proteins and methyltransferase complexes had poor survival benefits through influencing protein subcellular location in prostate cancer.
AbstractList N6-methyladenosine (m6A) is the most prevalent RNA modification. While the role of m6A in prostate cancer remains unknown. We aim to measure the effects of m6A methylation regulatory genes during the development and progression of prostate cancer.BACKGROUNDN6-methyladenosine (m6A) is the most prevalent RNA modification. While the role of m6A in prostate cancer remains unknown. We aim to measure the effects of m6A methylation regulatory genes during the development and progression of prostate cancer.We collected transcriptome information and gene-level alteration data from The Cancer Genome Atlas datasets. The log-rank test and Cox regression model were used to examine the prognosis value of m6A methylation regulatory genes of prostate cancer.METHODSWe collected transcriptome information and gene-level alteration data from The Cancer Genome Atlas datasets. The log-rank test and Cox regression model were used to examine the prognosis value of m6A methylation regulatory genes of prostate cancer.We discovered that most of m6A methylation regulators were highly expressed in aggressive prostate cancer. Univariable and multivariable Cox regression results showed that the expression of Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3), Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) and N6-adenosine-methyltransferase non-catalytic subunit (METTL14) and copy number variant of AlkB Homolog 5 (ALKBH5) were considerably associated with a recurrence-free survival of prostate cancer. Furthermore, a high level of m6A methylation in mRNA promotes the progression of prostate cancer via regulating subcellular protein localization.RESULTSWe discovered that most of m6A methylation regulators were highly expressed in aggressive prostate cancer. Univariable and multivariable Cox regression results showed that the expression of Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3), Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) and N6-adenosine-methyltransferase non-catalytic subunit (METTL14) and copy number variant of AlkB Homolog 5 (ALKBH5) were considerably associated with a recurrence-free survival of prostate cancer. Furthermore, a high level of m6A methylation in mRNA promotes the progression of prostate cancer via regulating subcellular protein localization.Patients with a high level of mRNA methylation resulted from overexpression of reader proteins and methyltransferase complexes had poor survival benefits through influencing protein subcellular location in prostate cancer.CONCLUSIONPatients with a high level of mRNA methylation resulted from overexpression of reader proteins and methyltransferase complexes had poor survival benefits through influencing protein subcellular location in prostate cancer.
N6-methyladenosine (m6A) is the most prevalent RNA modification. While the role of m6A in prostate cancer remains unknown. We aim to measure the effects of m6A methylation regulatory genes during the development and progression of prostate cancer. We collected transcriptome information and gene-level alteration data from The Cancer Genome Atlas datasets. The log-rank test and Cox regression model were used to examine the prognosis value of m6A methylation regulatory genes of prostate cancer. We discovered that most of m6A methylation regulators were highly expressed in aggressive prostate cancer. Univariable and multivariable Cox regression results showed that the expression of Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3), Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) and N6-adenosine-methyltransferase non-catalytic subunit (METTL14) and copy number variant of AlkB Homolog 5 (ALKBH5) were considerably associated with a recurrence-free survival of prostate cancer. Furthermore, a high level of m6A methylation in mRNA promotes the progression of prostate cancer via regulating subcellular protein localization. Patients with a high level of mRNA methylation resulted from overexpression of reader proteins and methyltransferase complexes had poor survival benefits through influencing protein subcellular location in prostate cancer.
Background: N6-methyladenosine (m6A) is the most prevalent RNA modification. While the role of m6A in prostate cancer remains unknown. We aim to measure the effects of m6A methylation regulatory genes during the development and progression of prostate cancer. Methods: We collected transcriptome information and gene-level alteration data from The Cancer Genome Atlas datasets. The log-rank test and Cox regression model were used to examine the prognosis value of m6A methylation regulatory genes of prostate cancer. Results: We discovered that most of m6A methylation regulators were highly expressed in aggressive prostate cancer. Univariable and multivariable Cox regression results showed that the expression of Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3), Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) and N6-adenosine-methyltransferase non-catalytic subunit (METTL14) and copy number variant of AlkB Homolog 5 (ALKBH5) were considerably associated with a recurrence-free survival of prostate cancer. Furthermore, a high level of m6A methylation in mRNA promotes the progression of prostate cancer via regulating subcellular protein localization. Conclusion: Patients with a high level of mRNA methylation resulted from overexpression of reader proteins and methyltransferase complexes had poor survival benefits through influencing protein subcellular location in prostate cancer.
Author Li, Xuesong
He, Shiming
Song, Gang
Zhou, Liqun
Ji, Guangjie
Gong, Yanqing
Huang, Cong
Author_xml – sequence: 1
  givenname: Guangjie
  surname: Ji
  fullname: Ji, Guangjie
  organization: Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Center of China, Beijing, China
– sequence: 2
  givenname: Cong
  surname: Huang
  fullname: Huang, Cong
  organization: Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Center of China, Beijing, China
– sequence: 3
  givenname: Shiming
  surname: He
  fullname: He, Shiming
  organization: Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Center of China, Beijing, China
– sequence: 4
  givenname: Yanqing
  surname: Gong
  fullname: Gong, Yanqing
  organization: Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Center of China, Beijing, China
– sequence: 5
  givenname: Gang
  surname: Song
  fullname: Song, Gang
  organization: Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Center of China, Beijing, China
– sequence: 6
  givenname: Xuesong
  surname: Li
  fullname: Li, Xuesong
  organization: Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Center of China, Beijing, China
– sequence: 7
  givenname: Liqun
  surname: Zhou
  fullname: Zhou, Liqun
  organization: Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Center of China, Beijing, China
BackLink https://www.ncbi.nlm.nih.gov/pubmed/32710725$$D View this record in MEDLINE/PubMed
BookMark eNpVkctLxDAQxoMouqsevUqPXrqmSaaPiyCLL1jwoucwmyY10iY1aRf2v7e6q-hphpkf3zy-OTl03mlCLjK6yMqcs2tsrGsWGeUgqgMyyyoBqYCyOvyTn5B5jO-U5gAiPyYnnBUZLRjMyGrpuz7oN-2i3egEHbbbaGPiTdLlt0nQzdji4ENM-uAb5-NgVbLBdtSJdV-1OOCgE4VO6XBGjgy2UZ_v4yl5vb97WT6mq-eHp-XtKlUC-JCqNRiGBTeq0FQgQJ0ZqIURa6S8yEBQBrkxUFKGFIGVWFJkwtSsopTnlJ-Sm51uP647XSvthoCt7IPtMGylRyv_d5x9k43fyEIwEJBPAld7geA_Rh0H2dmodNui036MkglWsEpQzic03aFqujUGbX7HZFR-OyC_HZA7Byb-8u9uv_TPy_knJSaFeA
CitedBy_id crossref_primary_10_1186_s12916_022_02561_4
crossref_primary_10_1155_2022_4030046
crossref_primary_10_1186_s12916_021_02148_5
crossref_primary_10_3389_fgene_2021_768041
crossref_primary_10_3390_cancers14205148
crossref_primary_10_1016_j_cellsig_2023_110726
crossref_primary_10_1007_s13577_023_00933_3
crossref_primary_10_1186_s12885_023_11741_1
crossref_primary_10_1089_cbr_2023_0033
crossref_primary_10_1007_s00018_023_04798_5
crossref_primary_10_1038_s41419_023_05627_0
crossref_primary_10_3390_genes13020378
crossref_primary_10_3389_fimmu_2021_735170
crossref_primary_10_1111_and_14422
crossref_primary_10_1155_2021_1436088
crossref_primary_10_3389_fonc_2022_914692
crossref_primary_10_3389_fgene_2022_1096071
crossref_primary_10_3389_fcell_2021_633927
crossref_primary_10_1155_2022_5774339
crossref_primary_10_3390_cancers16071303
crossref_primary_10_1186_s40364_023_00499_0
crossref_primary_10_1038_s41585_023_00851_x
crossref_primary_10_1111_cpr_13168
crossref_primary_10_1186_s12935_021_02438_1
crossref_primary_10_1038_s41420_022_00844_6
crossref_primary_10_1007_s12672_023_00817_w
crossref_primary_10_3390_cancers15082243
crossref_primary_10_3389_fonc_2021_805571
crossref_primary_10_7717_peerj_14334
crossref_primary_10_18632_aging_104064
crossref_primary_10_3389_fgene_2020_604597
crossref_primary_10_3390_biology10080809
crossref_primary_10_1089_omi_2021_0114
crossref_primary_10_1002_mc_23609
crossref_primary_10_3389_fcell_2023_1264552
crossref_primary_10_3892_or_2024_8747
crossref_primary_10_1007_s12672_023_00843_8
crossref_primary_10_3892_mmr_2022_12796
crossref_primary_10_4103_cjop_CJOP_D_22_00071
crossref_primary_10_1016_j_neo_2023_100912
crossref_primary_10_3389_fgene_2020_614566
crossref_primary_10_1016_j_bbcan_2023_188961
crossref_primary_10_3390_app11010213
Cites_doi 10.1111/j.1464-410X.2011.10703.x
10.1038/s41556-018-0045-z
10.1038/nature19342
10.1056/NEJMoa1315815
10.1093/nar/gkx1030
10.2147/OTT.S226796
10.1016/j.stem.2017.11.016
10.1002/ijc.29210
10.1038/nature11013
10.1016/j.canlet.2017.11.018
10.1016/j.eururo.2013.12.008
10.1038/s41593-017-0057-1
10.1038/nature20577
10.1002/hep.28885
10.1186/s12943-019-1084-1
10.1016/j.ymthe.2019.11.016
10.4161/rna.28800
10.1038/s41556-018-0174-4
10.1002/ijc.28808
10.1016/j.cell.2015.08.011
10.1038/nrm.2016.132
10.1186/s13014-017-0837-5
10.1016/j.canlet.2020.01.029
10.1038/s41586-020-2135-x
10.1038/nature14281
10.1186/s13045-017-0410-6
10.1093/nar/gky1012
10.1186/s12943-017-0647-2
10.1073/pnas.71.10.3971
10.1053/j.gastro.2014.06.041
10.1016/j.bbrc.2018.05.175
10.1186/1471-2407-10-341
10.1016/S1470-2045(06)70732-X
10.1038/leu.2014.16
10.1016/j.molcel.2016.03.021
10.1002/hep.29683
10.1073/pnas.1602883113
10.1126/sciadv.aar8263
10.1001/jamaoncol.2016.5983
10.1038/nature24678
10.1038/s41586-019-1016-7
ContentType Journal Article
Copyright Copyright © 2020 Ji et al.
Copyright_xml – notice: Copyright © 2020 Ji et al.
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7X8
5PM
DOI 10.18632/aging.103549
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Biology
EISSN 1945-4589
EndPage 14884
ExternalDocumentID 10_18632_aging_103549
32710725
Genre Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
53G
ADBBV
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
CGR
CUY
CVF
DIK
E3Z
ECM
EIF
FRP
GX1
HYE
KQ8
M48
NPM
O5R
O5S
OK1
PGMZT
RPM
W2D
AAYXX
CITATION
7X8
5PM
ID FETCH-LOGICAL-c453t-cb5f2a73fc7e04a55d1f5d4f4ba0371540256ff5802a0a528a80a24fd29003603
IEDL.DBID RPM
ISSN 1945-4589
IngestDate Tue Sep 17 21:17:37 EDT 2024
Sat Oct 26 04:31:05 EDT 2024
Fri Aug 23 02:25:45 EDT 2024
Sat Nov 02 12:30:16 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed false
IsScholarly true
Issue 14
Keywords RNA modification
prostate cancer
N6-methyladenosine
copy number variants
Language English
License This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c453t-cb5f2a73fc7e04a55d1f5d4f4ba0371540256ff5802a0a528a80a24fd29003603
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7425456/
PMID 32710725
PQID 2427294033
PQPubID 23479
PageCount 22
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_7425456
proquest_miscellaneous_2427294033
crossref_primary_10_18632_aging_103549
pubmed_primary_32710725
PublicationCentury 2000
PublicationDate 20200725
PublicationDateYYYYMMDD 2020-07-25
PublicationDate_xml – month: 7
  year: 2020
  text: 20200725
  day: 25
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Aging (Albany, NY.)
PublicationTitleAlternate Aging (Albany NY)
PublicationYear 2020
Publisher Impact Journals
Publisher_xml – name: Impact Journals
References He (10) 2017; 1
Skibbe (30) 2018; 2
Yang (41) 2020; 58
Rottman (6) 1974; 7
Tavazoie (7) 2015; 51
Wunderlich (23) 2018; 2
Semenza (18) 2016; 11
Wild (25) 2010; 1
de Marzo (4) 2014; 37
Wu (27) 2006; 7
Sun (13) 2017; 6
Shariat (26) 2012; 11
Luo (19) 2019; 1
Zuo (37) 2019; 56
Tavazoie (31) 2015; 16
Haitel (29) 2014; 6
Rajan (35) 2014; 1
Bray (1) 2015; 13
Wong (16) 2018; 6
Zhao (38) 2018; 2
Agell (33) 2014; 14
Wang (40) 2020; 2
Kang (28) 2017; 1
Hendrick (21) 2017; 55
Tian (39) 2019; 1
Hüttelmaier (11) 2019; 4
Xu (14) 2018; 2
Tavazoie (32) 2012; 48
Jaffrey (8) 2016; 53
Rao (20) 2014; 2
Huang (36) 2018; 4
Jin (15) 2018; 50
Wong (22) 2017; 1
vom Dorp (24) 2014; 13
D’Amico (2) 2017; 3
Ye (17) 2018; 41
Soller (9) 2016; 54
Bujnicki (5) 2018; 4
Gregory (12) 2016; 6
Yi (34) 2020; 47
Pinkawa (3) 2017; 1
References_xml – volume: 11
  start-page: 63
  year: 2012
  ident: 26
  article-title: Prognostic value of insulin-like growth factor II mRNA binding protein 3 in patients treated with radical prostatectomy.
  publication-title: BJU Int
  doi: 10.1111/j.1464-410X.2011.10703.x
  contributor:
    fullname: Shariat
– volume: 2
  start-page: 285
  year: 2018
  ident: 30
  article-title: Recognition of RNA N-methyladenosine by IGF2BP proteins enhances mRNA stability and translation.
  publication-title: Nat Cell Biol
  doi: 10.1038/s41556-018-0045-z
  contributor:
    fullname: Skibbe
– volume: 53
  start-page: 369
  year: 2016
  ident: 8
  article-title: m(6)A RNA methylation promotes XIST-mediated transcriptional repression.
  publication-title: Nature
  doi: 10.1038/nature19342
  contributor:
    fullname: Jaffrey
– volume: 37
  start-page: 1028
  year: 2014
  ident: 4
  article-title: AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1315815
  contributor:
    fullname: de Marzo
– volume: 4
  start-page: D303
  year: 2018
  ident: 5
  article-title: MODOMICS: a database of RNA modification pathways. 2017 update.
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/gkx1030
  contributor:
    fullname: Bujnicki
– volume: 1
  start-page: 9143
  year: 2019
  ident: 19
  article-title: RNA MA methyltransferase METTL3 promotes the growth of prostate cancer by regulating hedgehog pathway.
  publication-title: Onco Targets Ther
  doi: 10.2147/OTT.S226796
  contributor:
    fullname: Luo
– volume: 2
  start-page: 191
  year: 2018
  ident: 23
  article-title: METTL14 inhibits hematopoietic stem/progenitor differentiation and promotes leukemogenesis via mRNA MA modification.
  publication-title: Cell Stem Cell
  doi: 10.1016/j.stem.2017.11.016
  contributor:
    fullname: Wunderlich
– volume: 13
  start-page: E359
  year: 2015
  ident: 1
  article-title: Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.
  publication-title: Int J Cancer
  doi: 10.1002/ijc.29210
  contributor:
    fullname: Bray
– volume: 48
  start-page: 264
  year: 2012
  ident: 32
  article-title: Systematic discovery of structural elements governing stability of mammalian messenger RNAs.
  publication-title: Nature
  doi: 10.1038/nature11013
  contributor:
    fullname: Tavazoie
– volume: 41
  start-page: 11
  year: 2018
  ident: 17
  article-title: HBXIP-elevated methyltransferase METTL3 promotes the progression of breast cancer via inhibiting tumor suppressor let-7g.
  publication-title: Cancer Lett
  doi: 10.1016/j.canlet.2017.11.018
  contributor:
    fullname: Ye
– volume: 6
  start-page: 379
  year: 2014
  ident: 29
  article-title: Insulin-like growth factor messenger RNA-binding protein 3 expression helps prognostication in patients with upper tract urothelial carcinoma.
  publication-title: Eur Urol
  doi: 10.1016/j.eururo.2013.12.008
  contributor:
    fullname: Haitel
– volume: 2
  start-page: 195
  year: 2018
  ident: 38
  article-title: N-methyladenosine RNA modification regulates embryonic neural stem cell self-renewal through histone modifications.
  publication-title: Nat Neurosci
  doi: 10.1038/s41593-017-0057-1
  contributor:
    fullname: Zhao
– volume: 54
  start-page: 301
  year: 2016
  ident: 9
  article-title: MA potentiates sxl alternative pre-mRNA splicing for robust drosophila sex determination.
  publication-title: Nature
  doi: 10.1038/nature20577
  contributor:
    fullname: Soller
– volume: 6
  start-page: 529
  year: 2017
  ident: 13
  article-title: METTL14 suppresses the metastatic potential of hepatocellular carcinoma by modulating N-methyladenosine-dependent primary MicroRNA processing.
  publication-title: Hepatology
  doi: 10.1002/hep.28885
  contributor:
    fullname: Sun
– volume: 1
  start-page: 168
  year: 2019
  ident: 39
  article-title: Mettl14 inhibits bladder TIC self-renewal and bladder tumorigenesis through N-methyladenosine of Notch1.
  publication-title: Mol Cancer
  doi: 10.1186/s12943-019-1084-1
  contributor:
    fullname: Tian
– volume: 2
  start-page: 599
  year: 2020
  ident: 40
  article-title: METTL14 suppresses CRC progression via regulating N6-methyladenosine-dependent primary miR-375 processing.
  publication-title: Mol Ther
  doi: 10.1016/j.ymthe.2019.11.016
  contributor:
    fullname: Wang
– volume: 1
  start-page: 755
  year: 2014
  ident: 35
  article-title: The RNA-binding protein hnRNPA2 regulates β-catenin protein expression and is overexpressed in prostate cancer.
  publication-title: RNA Biol
  doi: 10.4161/rna.28800
  contributor:
    fullname: Rajan
– volume: 2
  start-page: 1074
  year: 2018
  ident: 14
  article-title: MA mRNA methylation regulates AKT activity to promote the proliferation and tumorigenicity of endometrial cancer.
  publication-title: Nat Cell Biol
  doi: 10.1038/s41556-018-0174-4
  contributor:
    fullname: Xu
– volume: 13
  start-page: 1596
  year: 2014
  ident: 24
  article-title: Prognostic value of tissue and circulating levels of IMP3 in prostate cancer.
  publication-title: Int J Cancer
  doi: 10.1002/ijc.28808
  contributor:
    fullname: vom Dorp
– volume: 16
  start-page: 1299
  year: 2015
  ident: 31
  article-title: HNRNPA2B1 is a mediator of m(6)A-dependent nuclear RNA processing events.
  publication-title: Cell
  doi: 10.1016/j.cell.2015.08.011
  contributor:
    fullname: Tavazoie
– volume: 1
  start-page: 31
  year: 2017
  ident: 10
  article-title: Post-transcriptional gene regulation by mRNA modifications.
  publication-title: Nat Rev Mol Cell Biol
  doi: 10.1038/nrm.2016.132
  contributor:
    fullname: He
– volume: 1
  start-page: 98
  year: 2017
  ident: 3
  article-title: Long-term prognostic significance of rising PSA levels following radiotherapy for localized prostate cancer - focus on overall survival.
  publication-title: Radiat Oncol
  doi: 10.1186/s13014-017-0837-5
  contributor:
    fullname: Pinkawa
– volume: 47
  start-page: 43
  year: 2020
  ident: 34
  article-title: Loss of hnRNPA2B1 inhibits Malignant capability and promotes apoptosis via down-regulating Lin28B expression in ovarian cancer.
  publication-title: Cancer Lett
  doi: 10.1016/j.canlet.2020.01.029
  contributor:
    fullname: Yi
– volume: 58
  start-page: 93
  year: 2020
  ident: 41
  article-title: A genomic and epigenomic atlas of prostate cancer in Asian populations.
  publication-title: Nature
  doi: 10.1038/s41586-020-2135-x
  contributor:
    fullname: Yang
– volume: 51
  start-page: 482
  year: 2015
  ident: 7
  article-title: N6-methyladenosine marks primary microRNAs for processing.
  publication-title: Nature
  doi: 10.1038/nature14281
  contributor:
    fullname: Tavazoie
– volume: 1
  start-page: 39
  year: 2017
  ident: 22
  article-title: Genetic alterations of MA regulators predict poorer survival in acute myeloid leukemia.
  publication-title: J Hematol Oncol
  doi: 10.1186/s13045-017-0410-6
  contributor:
    fullname: Wong
– volume: 4
  start-page: 375
  year: 2019
  ident: 11
  article-title: IGF2BP1 promotes SRF-dependent transcription in cancer in a m6A- and miRNA-dependent manner.
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/gky1012
  contributor:
    fullname: Hüttelmaier
– volume: 1
  start-page: 77
  year: 2017
  ident: 28
  article-title: IGF2BP3 functions as a potential oncogene and is a crucial target of miR-34a in gastric carcinogenesis.
  publication-title: Mol Cancer
  doi: 10.1186/s12943-017-0647-2
  contributor:
    fullname: Kang
– volume: 7
  start-page: 3971
  year: 1974
  ident: 6
  article-title: Identification of methylated nucleosides in messenger RNA from novikoff hepatoma cells.
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.71.10.3971
  contributor:
    fullname: Rottman
– volume: 14
  start-page: 882
  year: 2014
  ident: 33
  article-title: Ribonucleoprotein HNRNPA2B1 interacts with and regulates oncogenic KRAS in pancreatic ductal adenocarcinoma cells.
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2014.06.041
  contributor:
    fullname: Agell
– volume: 50
  start-page: 456
  year: 2018
  ident: 15
  article-title: MA demethylase FTO facilitates tumor progression in lung squamous cell carcinoma by regulating MZF1 expression.
  publication-title: Biochem Biophys Res Commun
  doi: 10.1016/j.bbrc.2018.05.175
  contributor:
    fullname: Jin
– volume: 1
  start-page: 341
  year: 2010
  ident: 25
  article-title: Insulin-like growth factor II mRNA binding protein 3 (IMP3) is overexpressed in prostate cancer and correlates with higher gleason scores.
  publication-title: BMC Cancer
  doi: 10.1186/1471-2407-10-341
  contributor:
    fullname: Wild
– volume: 7
  start-page: 556
  year: 2006
  ident: 27
  article-title: Analysis of RNA-binding protein IMP3 to predict metastasis and prognosis of renal-cell carcinoma: a retrospective study.
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(06)70732-X
  contributor:
    fullname: Wu
– volume: 2
  start-page: 1171
  year: 2014
  ident: 20
  article-title: WTAP is a novel oncogenic protein in acute myeloid leukemia.
  publication-title: Leukemia
  doi: 10.1038/leu.2014.16
  contributor:
    fullname: Rao
– volume: 6
  start-page: 335
  year: 2016
  ident: 12
  article-title: The m(6)A methyltransferase METTL3 promotes translation in human cancer cells.
  publication-title: Mol Cell
  doi: 10.1016/j.molcel.2016.03.021
  contributor:
    fullname: Gregory
– volume: 6
  start-page: 2254
  year: 2018
  ident: 16
  article-title: RNA N6-methyladenosine methyltransferase-like 3 promotes liver cancer progression through YTHDF2-dependent posttranscriptional silencing of SOCS2.
  publication-title: Hepatology
  doi: 10.1002/hep.29683
  contributor:
    fullname: Wong
– volume: 11
  start-page: E2047
  year: 2016
  ident: 18
  article-title: Hypoxia induces the breast cancer stem cell phenotype by HIF-dependent and ALKBH5-mediated mA-demethylation of NANOG mRNA.
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.1602883113
  contributor:
    fullname: Semenza
– volume: 4
  start-page: eaar8263
  year: 2018
  ident: 36
  article-title: Cross-talk among writers, readers, and erasers of MA regulates cancer growth and progression.
  publication-title: Sci Adv
  doi: 10.1126/sciadv.aar8263
  contributor:
    fullname: Huang
– volume: 3
  start-page: 652
  year: 2017
  ident: 2
  article-title: Surrogate end points for all-cause mortality in men with localized unfavorable-risk prostate cancer treated with radiation therapy vs radiation therapy plus androgen deprivation therapy: a secondary analysis of a randomized clinical trial.
  publication-title: JAMA Oncol
  doi: 10.1001/jamaoncol.2016.5983
  contributor:
    fullname: D’Amico
– volume: 55
  start-page: 126
  year: 2017
  ident: 21
  article-title: Promoter-bound METTL3 maintains myeloid leukaemia by MA-dependent translation control.
  publication-title: Nature
  doi: 10.1038/nature24678
  contributor:
    fullname: Hendrick
– volume: 56
  start-page: 414
  year: 2019
  ident: 37
  article-title: Histone H3 trimethylation at lysine 36 guides MA RNA modification co-transcriptionally.
  publication-title: Nature
  doi: 10.1038/s41586-019-1016-7
  contributor:
    fullname: Zuo
SSID ssj0065546
Score 2.4974267
Snippet N6-methyladenosine (m6A) is the most prevalent RNA modification. While the role of m6A in prostate cancer remains unknown. We aim to measure the effects of m6A...
Background: N6-methyladenosine (m6A) is the most prevalent RNA modification. While the role of m6A in prostate cancer remains unknown. We aim to measure the...
SourceID pubmedcentral
proquest
crossref
pubmed
SourceType Open Access Repository
Aggregation Database
Index Database
StartPage 14863
SubjectTerms AlkB Homolog 5, RNA Demethylase - metabolism
Gene Expression Regulation, Neoplastic
Heterogeneous-Nuclear Ribonucleoprotein Group A-B - metabolism
Humans
Male
Methylation
Methyltransferases - genetics
Methyltransferases - metabolism
Prognosis
Progression-Free Survival
Prostatic Neoplasms - genetics
Prostatic Neoplasms - metabolism
Prostatic Neoplasms - pathology
Research Paper
RNA Processing, Post-Transcriptional
RNA-Binding Proteins - metabolism
SummonAdditionalLinks – databaseName: Scholars Portal Journals: Open Access(OpenAccess)
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LS8NAEB60YulFtL7iixXEWzTdR5IeRIpYilhPFnoL280uLWiiaQv237uTpLW1nrwm2T18O8N8k535BuDKkrY4toHNtbE-drmRgSs1067yTYh9jVQY7HfuvvidHn_qi_6PpFAJ4PjP1A7nSfWyt5uvz9m9dfg7dPjQZ_Q2n-eD7eM22dmELYqaXFjFxxcXCj4WY5USm2tLalBl1EbaAOdlL0enNcr5u3JyKRS1d2Gn5JCkVRz6HmzopA7bxVTJWR2q3fK-fB-e0d0zPSyq1IksFUhIasi73yJZMYg-zcYE67SSFEWbCep_azJK8Fneb0QUmkZ2AL324-tDxy3nJ7iKCzZx1UAYKgNmVKA9LoWIG0bE3PCBRKE-y9Us3zFGhB6VnhQ0lKEnKTcxxd-bvscOoZKkiT4G0lANrowObDalkHKFzZApKgeBok3DTODA9Ry36KOQyYgwvUCsoxzrqMDagcs5qpE1ZLydkIlOp-PIcgVL9LnHmANHBcqLrebH40Cwgv_iAxTJXn2TjIa5WLZN_ZEknvx75SnUKObYHipanEFlkk31uSUik8FFbmLfAHff7Q
  priority: 102
  providerName: Scholars Portal
Title Comprehensive analysis of m6A regulators prognostic value in prostate cancer
URI https://www.ncbi.nlm.nih.gov/pubmed/32710725
https://www.proquest.com/docview/2427294033
https://pubmed.ncbi.nlm.nih.gov/PMC7425456
Volume 12
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LS8NAEB5sQfEivo2PsoJ4S5vsI0mPRaxFjHhQ6C1sNru0YJOStgf_vTt5iI-blxzyInyZZL5JvvkG4MaStiyzic21uT5zuZGhKzXTrgpMhH2NVBjsd46fg8kbf5yK6RaIthemEu2rdN7P3xf9fD6rtJXLhRq0OrHBS3xnyzlM_IMOdGyAtiV6_foNUHbVmGlGAaODatgP9pbbSmgXdhi1OTXEydjf89AfcvlbI_kt6Yz3Ya9hi2RUX9UBbOn8ELbr-ZEfh7ATN3_Gj-AJH-xSz2o9OpGN1wgpDFkEI1LWI-eLckVQkZUXaM9M0Olbk3mO66rOIqIwCMpjeBvfv95N3GZSgqu4YGtXpcJQGTKjQu1xKUTmG5Fxw1OJlnyWlVlmY4yIPCo9KWgkI09SbjKKHzIDj51ANy9yfQbEVz5XRoe2blJIrqJhxBSVaajo0DATOnDb4pYsa0OMBAsJxDqpsE5qrB24blFNbMjifwiZ62KzSiwrsJSee4w5cFqj_HWq9vY4EP7A_2sHtMP-ucVGSWWL3UTF-b-PvIBditW0h94Vl9Bdlxt9ZSnHOu1B52Hq22XMo14Vbp-GkNpd
link.rule.ids 230,315,730,783,787,888,2228,24332,27938,27939,53806,53808
linkProvider National Library of Medicine
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3JTsMwEB1BEcuFfSmrkRC3tKmXJD0iBCrQIg6AuEWOY4sKmqDQHuDr8cQJYjnBNZsSPdvzJn7zBuDIkrY0tYHNs7E-9biRoSc1054KTIR1jVQYrHceXAe9O375IB6mQNS1MKVoXyXDVvY8amXDx1Jb-TJS7Von1r4ZnNp0DgN_expm7Hz1gzpJdwtwgMKryk4zChhtl-1-sLrc5kILMMeojaoh9sb-Gol-0cufKskvYed8Ce7rF3Zqk6fWZJy01PsPL8c_f9EyLFZElJy40yswpbNVmHWtKd9WYW5QbbqvQR_XjEI_Oqk7kZWNCckNGQUnpHDd7PPilaDYK8vR-ZmgibgmwwyPlUVLROH4Ktbh7vzs9rTnVU0YPMUFG3sqEYbKkBkVap9LIdKOESk3PJHo9mcJnyVNxojIp9KXgkYy8iXlJqX4jzTw2QY0sjzTW0A6qsOV0aFNyRTytqgbMUVlEiraNcyETTiuAYlfnNdGjDkKghiXIMYOxCYc1nDFdjbgFofMdD55jS3hsNkC9xlrwqaD7_NRNe5NCL8B-3kBOm1_P2PhKh23K3i2_33nAcz3bgf9uH9xfbUDCxSTdh8tMnahMS4mes8ym3GyX47jD4Dq-os
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT9tAEB6VVES50BJe6YtFQtwcO_uwnSOijSgQlANIiIu1Xu8qURs7cpID_fXd8doowI2rX7L17e584_3mG4BTS9qyzAY2z8b6zONGRp7UTHsqNDHWNVJhsN55fBte3vOrB_Gw0eqrEu2rdNbP_877-WxaaSsXc-U3OjF_Mr6w6RwGfn-RGX8LPto5G8RNou4W4RDFV7WlZhwy6lctf7DC3OZDHWgzaiNrhP2xN6PRG4r5Wim5EXpGn-CxeWmnOPnTX6_Svvr3ys_xXV_1GXZqQkrO3SW78EHnXdh2LSqfutAe15vve3CDa0epp07yTmRtZ0IKQ-bhOSldV_uiXBIUfeUFOkATNBPXZJbjsap4iSgcZ-U-3I9-3V1cenUzBk9xwVaeSoWhMmJGRTrgUohsYETGDU8luv5Z4mfJkzEiDqgMpKCxjANJucko_isNA3YArbzI9RGQgRpwZXRkUzOF_C0exkxRmUaKDg0zUQ_OGlCShfPcSDBXQSCTCsjEAdmDkwayxM4K3OqQuS7Wy8QSD5s18ICxHhw6CJ8f1WDfg-gFuM8XoOP2yzMWssp5u4boy7vvPIb25Ocoufl9e_0VOhRz9wCdMr5Ba1Wu9XdLcFbpj2oo_wdd7_0L
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Comprehensive+analysis+of+m6A+regulators+prognostic+value+in+prostate+cancer&rft.jtitle=Aging+%28Albany%2C+NY.%29&rft.au=Ji%2C+Guangjie&rft.au=Huang%2C+Cong&rft.au=He%2C+Shiming&rft.au=Gong%2C+Yanqing&rft.date=2020-07-25&rft.pub=Impact+Journals&rft.eissn=1945-4589&rft.volume=12&rft.issue=14&rft.spage=14863&rft.epage=14884&rft_id=info:doi/10.18632%2Faging.103549&rft_id=info%3Apmid%2F32710725&rft.externalDBID=PMC7425456
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1945-4589&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1945-4589&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1945-4589&client=summon